Company profile
Orchestra BioMed Holdings, Inc.
NASDAQ: OBIO · Healthcare · Biotechnology
#486 of 1,418 Healthcare companies by revenuetop-decile growth
EA Score
46DFH 47DQ 33GM 66SS 53
v0.1 · 65/100 weight · provisional
↑ revenue growth (YoY), 3-yr revenue growth · ↓ growth stability, disclosure history
Methodology →Revenue TTM
$32.7M
Rev growth YoY (TTM)
+1033.9%
Net income (FY)
-$52.7M
Employees
86
as of 2026-08-13
Market cap
$264.7M
as of 2026-08-13
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$33.5M$33.5M2025
Net income-$52.7M-$52.7M2025
Operating income-$51.8M-$51.8M2025
Total assets$114.9M$114.9M2025
Liabilities$51.5M$51.5M2025
Equity$53.6M$53.6M2025
Revenue trend
FY2023 – FY2025 · USD
FY23
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Product100%
By geography
Not disclosed.
The read
What is Orchestra BioMed Holdings, Inc.’s revenue?
Orchestra BioMed Holdings, Inc. booked $33.5M in FY2025 revenue, growing 1169% year over year — faster than 96% of Healthcare companies we track, at a -157.4% net margin.
Peers · Healthcare
X4 Pharmaceuticals, Inc.51DPrecision BioSciences, Inc.46DRapid Micro Biosystems, Inc.46DArcus Biosciences, Inc.47DC21 Investments Inc.49DGrown Rogue International Inc.52DNeighbors
Bucks →Key facts
CEODavid Hochman
SectorHealthcare
IndustryBiotechnology
HeadquartersNew Hope, PA
ExchangeNASDAQ: OBIO
Employees86
IPO date2020-08-04
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.